Division of Gastric Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Cancer Multiomics Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Gastric Cancer. 2024 Jul;27(4):760-771. doi: 10.1007/s10120-024-01506-5. Epub 2024 May 14.
Microsatellite instability-high (MSI-H) tumors are distinct molecular subtypes in gastric cancer. However, a few studies have comprehensively reported the molecular features of MSI-H tumors and their prognostic factors in locally advanced gastric cancer. This study aimed to clarify the molecular features and prognostic factors of locally advanced MSI-H gastric cancer.
This study included 499 patients with locally advanced gastric cancer who underwent radical gastrectomy. We evaluated the MSI status and compared with previously published whole-exome sequencing, panel sequencing, and gene expression profiling data. Clinicopathological characteristics and molecular profiles were compared between patients with MSI-H and microsatellite stable (MSS) gastric cancer. A subgroup analysis of survival was performed in patients with MSI-H gastric cancer.
MSI-H tumors were detected in 79 of 499 patients (15.8%). MSI-H tumors were associated with an increased tumor mutational burden, MLH1 downregulation, CD274 (PD-L1) upregulation, and enrichment of cell cycle pathways. Among patients with MSI-H gastric cancer, the disease-specific survival (DSS) tended to be better in the surgery plus tegafur, gimeracil, and oteracil potassium (S-1) adjuvant chemotherapy group than in the surgery alone group, especially for stage III patients. Furthermore, DSS was better in the T cell-inflamed gene expression signature-high group, and it tended to be worse in the non-solid type poorly differentiated adenocarcinoma group.
The molecular features and prognostic factors of locally advanced MSI-H gastric cancer were clarified. S-1 adjuvant chemotherapy appears to be beneficial, and the T cell-inflamed gene expression signature and histopathological type are prognostic factors in MSI-H tumors.
微卫星不稳定高(MSI-H)肿瘤是胃癌的独特分子亚型。然而,少数研究全面报道了局部进展期胃癌中 MSI-H 肿瘤的分子特征及其预后因素。本研究旨在阐明局部进展期 MSI-H 胃癌的分子特征和预后因素。
本研究纳入了 499 例接受根治性胃切除术的局部进展期胃癌患者。我们评估了 MSI 状态,并与先前发表的全外显子测序、面板测序和基因表达谱数据进行了比较。比较了 MSI-H 和微卫星稳定(MSS)胃癌患者的临床病理特征和分子特征。对 MSI-H 胃癌患者进行了生存亚组分析。
在 499 例患者中,有 79 例(15.8%)检测到 MSI-H 肿瘤。MSI-H 肿瘤与肿瘤突变负荷增加、MLH1 下调、CD274(PD-L1)上调以及细胞周期途径富集相关。在 MSI-H 胃癌患者中,手术加替吉奥、吉美嘧啶和奥替拉西钾(S-1)辅助化疗组的疾病特异性生存率(DSS)倾向于优于单纯手术组,尤其是对于 III 期患者。此外,T 细胞炎症基因表达谱高的患者 DSS 更好,非实性低分化腺癌的患者 DSS 更差。
阐明了局部进展期 MSI-H 胃癌的分子特征和预后因素。S-1 辅助化疗可能有益,T 细胞炎症基因表达谱和组织病理学类型是 MSI-H 肿瘤的预后因素。